Search PSNL
Personalis, Inc.
Nasdaq · CIK 1527753
Last close16.28
Daily change+0.11 (0.68%)
10 Years gain-42.86%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PSNL · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
24.9Momentum
0.0Acceleration
0.0Confidence
74.0Annual Revenue9
Quarterly Revenue35
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth3.1 / 25
Quality10.9 / 25
Capital Efficiency0.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 16.484 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 81.1481 percentage points.
Heavy share dilution · HIGHDiluted share count increased 20.5351%.
Low interest coverage · HIGHInterest coverage is -565.5459x.
ROIC declining · MEDIUMROIC declined by 170.7595 percentage points.
Key Metrics
Revenue Growth TTM-18.87%OK
Revenue CAGR 3Y2.3%OK
Gross Margin16.82%OK
Operating Margin-159.43%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-396.6%OK
Incremental Operating Margin 3Y103.5%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y20.54%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $69.65M | $15.78M | -$88.06M | -$74.95M | -$79.45M | 22.65% | -126.43% | -114.07% | -355.1% | 89.24M |
| 2025 FY Dec 31, 2024 | $84.61M | $26.83M | -$68.27M | -$45.15M | -$46.75M | 31.7% | -80.68% | -55.25% | -324.79% | 59.25M |
| 2024 FY Dec 31, 2023 | $73.48M | $18.21M | -$109.94M | -$56.26M | -$67.17M | 24.78% | -149.61% | -91.41% | -264.21% | 48.18M |
| 2023 FY Dec 31, 2022 | $65.05M | $13.35M | -$115.53M | -$70.23M | -$120.13M | 20.52% | -177.61% | -184.68% | -247.62% | 45.7M |
| 2023 FY Dec 31, 2021 | $85.49M | $31.66M | -$65.35M | -$70.83M | -$81.91M | 37.03% | -76.44% | -95.81% | -693.38% | 43.89M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $69.53M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-332817, 0001193125-25-264708 |
| Revenue Growth TTM | -18.87% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-332817, 0001193125-25-264708 |
| Revenue CAGR 3Y | 2.3% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076615 |
| Revenue CAGR 5Y | -2.4% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076615 |
| Gross Profit CAGR 3Y | 5.73% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076615 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-332817, 0001193125-25-264708 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 16.82% | Gross Profit / Revenue | OK | 0001193125-26-332817, 0001193125-25-264708 |
| Operating Margin | -159.43% | Operating Income / Revenue | OK | 0001193125-26-332817, 0001193125-25-264708 |
| ROIC | -396.6% | NOPAT / Average Invested Capital | OK | 0001193125-26-332817, 0001193125-25-264708 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332817 |
| Interest Coverage | -565.55x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 5.28x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.66 | Revenue / Diluted Shares | OK | 0001193125-26-332817, 0001193125-25-264708 |